Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 11 of 26
Non-contrast DWI for Supplemental Screening
University of Washington
NCT03607552
Intraoperative Radiation Therapy (IORT) in DCIS
Columbia University
NCT03216421
Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)
NYU Langone Health
NCT03927768
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis Pharmaceuticals
NCT01872260
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
UNC Lineberger Comprehensive Cancer Center
NCT05926024
Elevate! : An Elderly Breast Cancer Cohort Study
Dana-Farber Cancer Institute
NCT03818087
Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study
Memorial Sloan Kettering Cancer Center
NCT01517945
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Tolmar
NCT04906395
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
Carnegie Mellon University
NCT04651452
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
City of Hope Medical Center
NCT01030250
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02743910
Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery
KK Women's and Children's Hospital
NCT03408717
Proton Radiation for Stage II/III Breast Cancer
Proton Collaborative Group
NCT01758445
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Arvinas Estrogen Receptor
NCT04072952
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
Mayo Clinic
NCT04308720
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
NCT05677048
Robotic vs. Open NSM for Early Stage Breast Cancer
Intuitive Surgical
NCT05720039
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
Case Comprehensive Cancer Center
NCT04348123
Radiation Therapy in Treating Women With Early Stage Breast Cancer
Rutgers, The State University of New Jersey
NCT00909909
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05078190
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech
NCT03006172
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
Cedars-Sinai Medical Center
NCT02564848
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
University of Chicago
NCT03238976
Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic
Johns Hopkins University
NCT05181722
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
NCT02764541
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Eli Lilly and Company
NCT05307705
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Pfizer
NCT05262400
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03983382
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NYU Langone Health
NCT03400215
Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT03619083
T-Cell Therapy for Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT02792114
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
AstraZeneca
NCT04421963
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
Mayo Clinic
NCT03879629
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Genentech
NCT03332797
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
Dartmouth-Hitchcock Medical Center
NCT04568616
MARGetuximab Or Trastuzumab (MARGOT)
Dana-Farber Cancer Institute
NCT04425018
Exercise Post-Diagnosis of Breast Cancer
University of Hawaii
NCT04013568
Evaluating the Effects of Genetic Testing on Patients' Stress Levels
Medical College of Wisconsin
NCT02783664
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
NCT02326974
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT03255577
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
Dana-Farber Cancer Institute
NCT04717050
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
NCT04553133
Partial Breast Proton Therapy for Early Stage Breast Cancer
Loma Linda University
NCT01310530
Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies
Stanford University
NCT05916378
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
Complement Theory
NCT06397651
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors
City of Hope Medical Center
NCT01450020
Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT01943695
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
NCT00600496
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.